Bayer launches its blockbuster drug finerenone to treat chronic kidney disease (CKD) associated with type-II diabetes in India.This drug will be available as brand name of Kerendia in India.
India is becoming the hub of diabetes and CKD is common in people with diabetes. Approximately 1 in 3 adults with diabetes has CKD. Both type 1 and type 2 diabetes can cause kidney disease. where, finerenone is used to treat CKD associated with type-II diabetes.
- Read more about Bayer launches its blockbuster drug finerenone in India
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/bayer-launches-its-blockbuster-drug-finerenone-in-india
No comments:
Post a Comment